Gaspar Rui, Macedo Guilherme
Department of Gastroenterology, Centro Hospitalar e Universitário de São João, Porto, Portugal.
Faculty of Medicine of University of Porto, Porto, Portugal.
GE Port J Gastroenterol. 2024 Apr 22;31(6):377-387. doi: 10.1159/000538484. eCollection 2024 Dec.
Cirrhosis is one of the major causes of morbidity and mortality worldwide and the second leading cause of digestive disease mortality. Portal hypertension is the main driver of cirrhosis-related complications such as ascites and variceal bleeding. Portal hypertension is defined as a hepatic venous pressure gradient >5 mm Hg, although it is clinically significant and associated with clinical complications when >10 mm Hg.
Therefore, detection of clinically significant portal hypertension (CSPH) in chronic advanced liver disease or compensated cirrhosis is of paramount importance to guide the management of these patients.
This study aimed at revising the non-invasive and invasive tools for assessment of portal hypertension and risk stratification for CSPH in patients with chronic liver disease.
肝硬化是全球发病和死亡的主要原因之一，也是消化系统疾病死亡的第二大原因。门静脉高压是肝硬化相关并发症（如腹水和静脉曲张出血）的主要驱动因素。门静脉高压定义为肝静脉压力梯度>5 mmHg，尽管当>10 mmHg时具有临床意义并与临床并发症相关。
因此，在慢性晚期肝病或代偿期肝硬化中检测具有临床意义的门静脉高压（CSPH）对于指导这些患者的管理至关重要。
本研究旨在修订评估门静脉高压的非侵入性和侵入性工具以及慢性肝病患者CSPH的风险分层。
